Wyoming residents will soon benefit from a major cost reduction in insulin products, thanks to a settlement between the state’s attorney general and pharmaceutical company Sanofi-Aventis US Announced by Attorney General Bridget Hill, the agreement ensures that Wyoming residents not enrolled in government healthcare programs can purchase insulin for just $35 per month for the next five years.
The settlement will take effect within 90 days of September 27, 2024.
The move comes after concerns over the skyrocketing prices of insulin, which have surged over the past decade, placing a significant burden on individuals with diabetes. The attorney general’s office initiated the settlement to address potential deceptive pricing by insulin manufacturers. The reduced price mirrors the cap set for seniors on Medicare as part of President Joe Biden’s Inflation Reduction Act, which came into effect earlier this year.
Under the terms of the settlement, Wyoming residents paying cash for insulin products—including Admelog, Lantus, Toujeo, Apidra, and their biosimilars—will be eligible for the $35 price after registering for a savings card on Sanofi’s website. Additionally, Sanofi will implement an alert system at pharmacy counters across Wyoming to notify patients of the low-cost insulin option.
Attorney General Hill hailed the settlement as a significant step in combating high insulin prices.
“This settlement will greatly help Wyoming families needing insulin, allowing them to better manage their care without the fear of unaffordable costs,” she said.
Hill also emphasized that her office will continue investigating insulin pricing practices and raising awareness of the new affordability measures.
Sanofi will also maintain its Patient Connection Program, which provides free insulin to residents in financial need, further aiding Wyoming’s efforts to alleviate the financial burden of diabetes care.
Wyoming Tribune Eagle and Casper Star-Tribune contributed to this report.
